Pro-rEsolving and pRo-inflammatory reSPonses to Acute exhaustIve exeRcisE in Healthy Individuals

• Willingness and ability to provide informed consent and participate in PRESPIRE
• Able to read and speak English adequately to provide informed consent and understand verbal and written instructions. (the diet and sleep questionnaires are not validated in languages other than English)
• BMI \< 27kg/m2
• Untrained: self-reporting no more than 1 day per week of regular exercise (inclusive of walking >5,000 steps daily and commuting via bicycle).
• Trained: self-reporting at least 4 hours of aerobic exercise / moderate or greater intensity physical activity weekly for the past year.

Exclusion Criteria:

• Anti-platelet medication use
• Chronic inflammatory or connective tissue disease
• History of bleeding or clotting disorder
• Immunological deficiency
• Diabetes mellitus
• Stage 2 or greater hypertension on screening
• Cardiovascular disease
• Chronic obstructive lung disease
• Anemia (hemoglobin \<13g/dL in males or \< 12 g/dL in females)
• Active smoking
• >5% body weight change over the past 6 months or plan to gain/lose weight during the study
• Platelet count \<100,000
• Use of omega-3 fatty acid supplementation within 3 weeks of study participation
• Use of drugs or supplements known to inhibit COX-1/COX-2/lipoxygenases
• Corticosteroid use
• Use of beta-blocker medications
• Use of alpha-blocker medications
• Use of NSAIDs or aspirin within 2 weeks of study participation
• Vaccination within 2 weeks of study participation
• Pregnancy (a state of relative immunological deficiency)
• Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol.
• Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol